Document is current
Any future updates will be listed below
-
Authors
Holzleitner, Nadine https://orcid.org/0000-0001-8258-3526
Vilangattil, Meryl
Swaidan, Abir
Garcia-Prada, Clara Diaz
Taddio, Marco F.
Jeanjean, Pauline
Mona, Christine E.
Lapa, Constantin
Casini, Angela
Günther, Thomas
Carlucci, Giuseppe https://orcid.org/0000-0001-7494-335X
-
Funding
Funding for this research was provided by:
Bayerisch-Kalifornischen Hochschulzentrum (4 [2022-2])
Technische Universität München
- License Information
-
More Information
Article History
Received: 7 July 2024
Accepted: 20 September 2024
First Online: 11 October 2024
Declarations
:
: All animal studies were approved by the UCLA Institutional Animal Care and Use Committee, known as the Chancellor’s Animal Research Committee (ARC; # 2005–090). The institutional guidelines for the care and use of animals were strictly followed. Mice were housed under pathogen-free conditions. Water and food were provided ad libitum. 394-NOD SCID mice were injected subcutaneously into the shoulder region. Tumor growth was monitored by CT. Animals were sacrificed upon reaching any of the termination criteria specified in the ARC protocol, including but not limited to apathy, ulceration, severe weight loss, or other signs of deteriorating condition. The study was carried out in compliance with the ARRIVE guidelines. This article does not contain any studies with human participants.
: A patent application on CCK-2R-targeted ligands, including DOTA-CCK-66, has been filed, with NH, CL, and TG as co-inventors. No other potential conflict of interest relevant to this article was reported.
